A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the effect of LJPC-501 infusion on mean arterial
pressure (MAP) as assessed by standard of care vasopressor dose reduction in pediatric
patients with catecholamine-resistant hypotension (CRH). In addition, this study will
evaluate the safety and tolerability of LJPC-501 in pediatric patients, evaluate changes in
catecholamine and other vasopressor doses over time, evaluate the change in MAP over time,
and the change in Pediatric Logistic Organ Dysfunction-2 (PELOD-2) scores.
Phase:
Phase 2
Details
Lead Sponsor:
La Jolla Pharmaceutical Company
Treatments:
Angiotensin II Angiotensinogen Giapreza Pharmaceutical Solutions